<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739295</url>
  </required_header>
  <id_info>
    <org_study_id>L002</org_study_id>
    <nct_id>NCT02739295</nct_id>
  </id_info>
  <brief_title>G-CSF in the Treatment of Toxic Epidermal Necrolysis</brief_title>
  <acronym>NeupoNET</acronym>
  <official_title>Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis.
      This is a prospective randomized controlled trial.

      Patients will be allocated in a treatment group (receiving an injection of 5 microg/kg/d of
      G-CSF during 5 consecutive days) or in a placebo group. Patients will be randomized at
      admission and will be followed until 3 months after discharge.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time for healing</measure>
    <time_frame>From date of randomization until the date of complete healing, assessed up to 30 days.</time_frame>
    <description>Time for complete cutaneous healing, considered as healing of 90% of the body surface area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunohistology: Changes in immunohistologic typing (MAC 387, CD15, CD68, CD45Ro, fact XIIIa)</measure>
    <time_frame>At admission and at day 5</time_frame>
    <description>Changes in immunohistologic typing (MAC 387, CD15, CD68, CD45Ro, fact XIIIa)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological data: Neutrophilic count</measure>
    <time_frame>Every day during the 14th first days</time_frame>
    <description>Neutrophilic count</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological data: WBC count</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>WBC count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological data: WBC formula</measure>
    <time_frame>3 months after discharge</time_frame>
    <description>WBC formula</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Stevens - Johnson Syndrome</condition>
  <arm_group>
    <arm_group_label>G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant granulocyte - colony stimulating factor</intervention_name>
    <arm_group_label>G-CSF</arm_group_label>
    <other_name>Neupogen (Amgen)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0.9%</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Toxic epidermal necrolysis with SCORTEN 1 to 5 at admission

        Exclusion Criteria:

          -  Toxic epidermal necrolysis with SCORTEN 6 or 7 at admission

          -  Hypercoagulable state

          -  Cardiac or peripheral arterial disease

          -  Active malignancy

          -  Myelodysplastic syndrome or hematological malignancy

          -  Fructose intolerance

          -  Pregnancy

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
    <email>afrousseau@chu.ulg.ac.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Burn Centre of the University Hospital of Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Françoise Rousseau, MD, PhD</last_name>
      <email>afrousseau@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Military Hospital Burn Centre</name>
      <address>
        <city>Neder-Over-Heembeeck</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge Jennes, MD</last_name>
      <email>serge.jennes@mil.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Rousseau</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

